1
|
Gupta R, Trivedi S, Vaddi SP, Borgohain M, Mittal R, Pandit S, Mane A. Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population. Urol Ann 2023; 15:138-147. [PMID: 37304518 PMCID: PMC10252785 DOI: 10.4103/ua.ua_114_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 10/18/2021] [Accepted: 10/25/2021] [Indexed: 06/13/2023] Open
Abstract
Objective The present retrospective study evaluates the effectiveness and tolerability of alpha-blockers as monotherapy in patients with benign prostatic hyperplasia associated with lower urinary tract symptoms (LUTS). Materials and Methods A total of 335 male patients >50 years were categorized into four groups (Alfuzosin: 166, Silodosin: 67, Tamsulosin: 70, Prazosin: 32). The efficacy evaluated as a change in International Prostate Symptom Score (IPSS), peak flow rate (Qmax), residual urine volume, and relief from LUTS, and tolerability of the various alpha-blockers was assessed across the study group. Results At baseline, most of the patients in alfuzosin (60%), silodosin (77%), and tamsulosin (90%) groups presented with severe IPSS (20-35), whereas patients in the prazosin group (69%) presented with a moderate score. At the end of the study, the mean IPSS gradually improved to moderate (41%, 62%, 66%, and 28%) and mild (59%, 38%, 28%, and 72%) in the alfuzosin, silodosin, tamsulosin, and prazosin groups, respectively (P = 0.004), with improvement in mean change in residual urine volume and complete relief from LUTS symptoms with no surgical or radiological interventions. Overall, 194 adverse events (AEs) were observed in 38.8% of patients. Of the total AEs, patients in the alfuzosin, silodosin, tamsulosin, and prazosin groups experienced 21%, 22%, 39%, and 18% of AEs, respectively. Conclusion The nonselective alpha-adrenergic receptor antagonist, alfuzosin, emerged as noninferior in effectiveness and superior in tolerability than other selective alpha-blockers, silodosin, tamsulosin, and prazosin.
Collapse
Affiliation(s)
- Rahul Gupta
- Department of Urology, Government Medical College, Jammu, Jammu and Kashmir, India
| | - Sameer Trivedi
- Department of Urology, IMS-BHU, Varanasi, Uttar Pradesh, India
| | | | - Mrinal Borgohain
- Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India
| | - Rajan Mittal
- Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India
| | - Sucheta Pandit
- Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India
| | - Amey Mane
- Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India
| |
Collapse
|
2
|
Qin J, Li Z, Ma S, Ye L, Jin G, Su W. One-pot cascade ring enlargement of isatin-3-oximes to 2,4-dichloroquinazolines mediated by bis(trichloromethyl)carbonate and triarylphosphine oxide. PHOSPHORUS SULFUR 2020. [DOI: 10.1080/10426507.2020.1782910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Jinjing Qin
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Zhenhua Li
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Shengzhe Ma
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Lixian Ye
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Guoqiang Jin
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Weike Su
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| |
Collapse
|
3
|
Kwon Y. Use of saw palmetto ( Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol 2019; 28:1599-1606. [PMID: 31807332 DOI: 10.1007/s10068-019-00605-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 02/18/2019] [Accepted: 03/19/2019] [Indexed: 12/26/2022] Open
Abstract
Benign prostatic hyperplasia (BPH) is a noncancerous growth of the prostate. BPH commonly occurs in elderly men. Lower urinary tract symptoms (LUTS) secondary to BPH (LUTS/BPH) have significant impacts on their health. Saw palmetto (Serenoa repens) extract (SPE) has been evaluated for its effectiveness in improvement of LUTS/BPH at preclinical and clinical levels. Potential mechanisms of actions include anti-androgenic, pro-apoptotic, and anti-inflammatory effects. However, SPE efficacy was inconsistent, at least partly due to a lack of a standardized SPE formula. A hexane extract (free fatty acids, > 80%) provided more consistent results. Free fatty acids (lauric acid) were effective in inhibition of 5α-reductase, and phytosterol (β-sitosterol) reduced prostatic inflammation. Multiple actions derived from different constituents may contribute to SPE efficacy. Evaluation of the clinical relevance of these bioactive components is required for standardization of SPE, thereby enabling consistent efficacy and recommendations for the use in the prevention and treatment of BPH.
Collapse
Affiliation(s)
- Youngjoo Kwon
- Department of Food Science and Engineering, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760 Korea
| |
Collapse
|
4
|
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 2017; 197:S189-S197. [DOI: 10.1016/j.juro.2016.10.071] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/20/1992] [Indexed: 12/26/2022]
|
5
|
Shirakawa T, Haraguchi T, Shigemura K, Morishita S, Minayoshi K, Miyazaki J, Yamada Y, Miyake H, Tanaka K, Fujisawa M. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized multicenter study. Int J Urol 2012; 20:903-10. [DOI: 10.1111/iju.12055] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Accepted: 11/21/2012] [Indexed: 11/30/2022]
Affiliation(s)
- Toshiro Shirakawa
- Division of Urology; Department of Surgery Related; Faculty of Medicine; Kobe University Graduate School of Medicine
| | - Takahiro Haraguchi
- Division of Urology; Department of Surgery Related; Faculty of Medicine; Kobe University Graduate School of Medicine
| | - Katsumi Shigemura
- Division of Urology; Department of Surgery Related; Faculty of Medicine; Kobe University Graduate School of Medicine
| | | | | | - Jiro Miyazaki
- Department of Urology; Kobe Ekisaikai Hospital; Kobe
| | - Yuji Yamada
- Department of Urology; Hyogo Prefectural Amagasaki Hospital; Amagasaki; Hyogo; Japan
| | - Hideaki Miyake
- Division of Urology; Department of Surgery Related; Faculty of Medicine; Kobe University Graduate School of Medicine
| | - Kazushi Tanaka
- Division of Urology; Department of Surgery Related; Faculty of Medicine; Kobe University Graduate School of Medicine
| | - Masato Fujisawa
- Division of Urology; Department of Surgery Related; Faculty of Medicine; Kobe University Graduate School of Medicine
| |
Collapse
|
6
|
Abstract
PURPOSE OF REVIEW α1-Adrenoceptor blockers are the most frequently prescribed medical therapy in the treatment of lower urinary tract symptom suggestive of benign prostatic hyperplasia (LUTS/BPH). The purpose of this review is to highlight the evolution of adrenoceptor blockers with emphasis on newly approved drugs. RECENT FINDINGS Over the past years new formulations of several α1-adrenoceptor blockers were introduced to the market. Five long-acting α1-blockers are currently approved by the Food and Drug Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin and silodosin. Silodosin is the only adrenoceptor blocker that exhibits true selectivity for the α1-adrenoceptor subtypes. This unique adrenoceptor selectivity profile likely accounts for the very favorable cardiovascular safety profile. SUMMARY Tamsulosin, alfuzosin slow release and silodosin do not require dose titration. Alfuzosin, terazosin, doxazosin and silodosin have all been shown to be effective in relieving LUTS/BPH independent of prostate size. Low incidence of orthostatic hypotension has been reported for silodosin, but abnormal ejaculation is the most commonly reported adverse effect.
Collapse
|
7
|
|
8
|
Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence 2011; 5:483-90. [PMID: 22003286 PMCID: PMC3191925 DOI: 10.2147/ppa.s14032] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) will usually affect older men, of whom 50% over the age 60 years and almost 90% in their nineties will be bothered enough by their symptoms that they request some type of treatment. However, symptomatic bother may also affect men in their forties with a prevalence rate of almost 18%. The International Prostate Symptom Score (IPSS) has become the most widely used and best validated questionnaire to allow the patient to quantify the severity of his LUTS/BPH symptoms. This score has become the cornerstone in demonstrating the "rate of symptom response" for the patient who has been exposed to any type BPH management. Question 8 on the IPSS score is what is defined as the "Quality of Life" question or what is also termed the "Bothersome Index." The score out of 6 as declared by the patient will reflect the degree of concern that the patient is feeling about his symptoms and the reduction of the score after treatment is a statement of their improved quality of life. There are 2 families of accepted medical therapy to treat the symptoms of BPH and potentially prevent the most worrisome long-term sequelae of progression of BPH: urinary retention or the need for surgery. When defining the impact of the main types of medical therapy, the alpha blockers have been termed the "openers" and the 5 alpha-reductase inhibitors are described as the "shrinkers." Since they each offer a different mechanism of effect, the concept of combination therapy was raised and trialed many times over recent years. The final aspect of any medical therapy is the patient's satisfaction with the treatment and the side effects. In the CombAT (Combination of Avodart and Tamsulosin) trial a new assessment was developed and tested called the Patient's Perception of Study Medication (PPSM) which told the investigators if the patients, given free choice, would choose to take that combination of medication to treat their problem and stay on the medication.
Collapse
Affiliation(s)
- Jack Barkin
- Correspondence: Jack Barkin, 960 Lawrence Ave, West Suite 404, Toronto, Ontario, Canada M6A 3B5, Tel +1 416 256 2737, Fax +1 416 256 9098, Email
| |
Collapse
|
9
|
Staskin DR, Wein AJ, Andersson KE. Urinary incontinence: classification and pharmacological therapy. CIBA FOUNDATION SYMPOSIUM 2007; 151:289-306; discussion 306-17. [PMID: 2226065 DOI: 10.1002/9780470513941.ch15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Pharmacological therapy has been developed which can have significant impact in the management of many forms of urinary incontinence and voiding dysfunction. In general the clinical laboratory studies which have supported or challenged the efficacy of many of the commonly prescribed drugs for voiding dysfunction are often difficult to interpret and contradictory. The available clinical studies often do not demonstrate a lack of bias. Nor do they include an adequate number of subjects, use appropriate and sensitive methods of evaluation, employ double-blind placebo-controlled design, or appear statistically valid. Although the contribution of laboratory research has been of unquestionable value in the development of our current knowledge of lower urinary tract pharmacology it is difficult to interpret the results of in vitro pharmacological studies because of the array of experimental models used and the need to extrapolate to in vivo activity. This paper utilizes a functional scheme which classifies agents by their effects on urinary storage and emptying. The purpose of this review is to promote discussion of the application of uropharmacological investigation to the development of newer, more efficacious forms of drug therapy.
Collapse
Affiliation(s)
- D R Staskin
- Division of Urology, Harvard University School of Medicine, Beth Israel Hospital, Boston, MA 02215
| | | | | |
Collapse
|
10
|
Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol 2006; 51:57-66. [PMID: 16979287 DOI: 10.1016/j.eururo.2006.07.050] [Citation(s) in RCA: 117] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2006] [Accepted: 07/28/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Benign prostatic hyperplasia (BPH) is considered a frequent cause of bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS), although the physiopathologic mechanism through which BPH causes LUTS is not clear. Several morphologic and functional modifications of the bladder detrusor have been described in patients with BPH and could play a direct role in determining symptoms. The opinion is spreading that the enlarged prostates in patients with LUTS is nothing more than a mere bystander. Evidence has accumulated, however, supporting the role of BPH-related BOO as the direct cause determining bladder dysfunction and indirectly causing urinary symptoms. The present review addresses the bladder response to BOO, particularly focusing on the physiopathologic cascade that links obstructive BPH to bladder dysfunction. METHODS A literature review of peer-reviewed articles has been performed, including both in vivo and in vitro studies on human tissue and animal model experiments. RESULTS Epithelial and smooth muscle cells in the bladder wall are mechanosensitive, and in response to mechanical stretch stress caused by BOO, undergo modifications of gene expression and protein synthesis. This process involves several transduction mechanisms and finally alter the ultrastructure and physiology of cell membranes, cytoskeleton, contractile proteins, mitochondria, extracellular matrix, and neuronal networks. CONCLUSIONS BOO is the initiator of a physiopathologic cascade leading to deep changing of bladder structure and function. Before being a direct cause of storing-phase urinary symptoms, the bladder is the first innocent victim of prostatic obstruction.
Collapse
Affiliation(s)
- Vincenzo Mirone
- Urologic Clinic, University Federico II of Naples, Naples, Italy.
| | | | | | | |
Collapse
|
11
|
Abstract
Alfuzosin (UroXatral, Sanofi-Synthelabo) a quinazoline derivative, has well-documented alpha(1)-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.
Collapse
Affiliation(s)
- David M Weiner
- Urology, Columbia University College of Physicians and Surgeons, 425 West 59th Street Suite 3A, New York, NY 10019, USA.
| | | |
Collapse
|
12
|
Costa WS, de Carvalho AM, Babinski MA, Chagas MA, Sampaio FJB. Volumetric density of elastic and reticular fibers in transition zone of controls and patients with benign prostatic hyperplasia. Urology 2004; 64:693-7. [PMID: 15491703 DOI: 10.1016/j.urology.2004.05.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2004] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To analyze the volumetric density (Vv) of elastic and reticular fibers in the transition zone of controls and patients with benign prostatic hyperplasia (BPH). METHODS Prostatic tissue samples were obtained from 25 patients (age range 63 to 79 years, mean 68) with clinical symptoms of bladder outlet obstruction who had undergone open prostatectomy. The control group was composed of 25 transition zone samples from prostates obtained during autopsy of adults aged younger than 30 years (killed in accidents). The Vv of the elastic and reticular fibers was determined in 25 random fields per prostate, using the point-count method with an M-42 grid test system. The data were analyzed using the Kolmogorov-Smirnov, Shapiro-Wilk W, and Mann-Whitney U tests. The Vv of these components was determined by stereologic methods. RESULTS The Vv in the control and BPH groups was 12.47% +/- 3.6% and 16.55% +/- 9.11% in the elastic system fibers (difference not statistically significant) and 22.75% +/- 1.66% and 29.33% +/- 1.08% in the reticular fibers (difference statistically significant), respectively. CONCLUSIONS Reticular fibers showed a statistically significant increase in the BPH samples, and this finding suggests that stromal network fibers play a significant role in BPH.
Collapse
Affiliation(s)
- Waldemar S Costa
- Urogenital Research Unit, Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, Brazil
| | | | | | | | | |
Collapse
|
13
|
Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y, Koji T. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 2003; 88:1333-40. [PMID: 12629127 DOI: 10.1210/jc.2002-021015] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Estrogen, which acts through estrogen receptors (ERs) alpha and beta, has been implicated in the pathogenesis of benign and malignant human prostatic tumors, i.e. benign prostatic hyperplasia and prostate cancer, thought to originate from different zones of the prostate [the transition zone (TZ) and peripheral zone (PZ), respectively]. Here, we examined the cellular distribution of ERalpha and ERbeta in human normal and hyperplastic prostate tissues, using in situ hybridization and immunohistochemistry. ERalpha expression was restricted to stromal cells of PZ. In contrast, ERbeta was expressed in the stromal cells of PZ as well as TZ. ERbeta-positive epithelial cells were evenly distributed in PZ and TZ of the prostate. Our results suggest that estrogen may play a crucial role in the pathogenesis of benign prostatic hyperplasia through ERbeta.
Collapse
Affiliation(s)
- Toshifumi Tsurusaki
- Department of Urology, The Japanese Red Cross Nagasaki Atomic Bomb Hospital, Nagasaki 852-8511, Japan
| | | | | | | | | | | | | |
Collapse
|
14
|
Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev 2001; 22:342-88. [PMID: 11399748 DOI: 10.1210/edrv.22.3.0430] [Citation(s) in RCA: 128] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
This review is designed to help the reproductive endocrinologist integrate his or her professional activity with those of other disciplines including urology, radiology, neurology, and psychology in order to successfully manage all of the inseparable aspects of male sexual and reproductive functioning. Significant advances in the field of male sexual physiology and pathophysiology and new methods of investigation and treatment of male sexual disorders are outlined. The review synthesizes available data on the following: norms of sexual organs, aging and sexuality, role of central and peripheral neurochemicals in each stage of the sexual cycle, role of corporeal smooth muscles in the hemodynamic control of erection and detumescence, influence of psychological factors, drugs, and disease on all aspects of sexual functioning, and use of nocturnal penile tumescence monitoring, imaging investigations, and neurophysiologic studies in the diagnostic workup of males with sexual dysfunction. Clinical algorithms are presented where appropriate. Extensive discussions on newly developed strategies in psychological and behavioral counseling, drug therapy, tissue engineering, nonsurgical devices, and surgical treatments for all forms of sexual disorders are also provided. Lastly, the effect of sexual dysfunction and its treatment on quality of life in affected men is addressed, along with recommendations for future research endeavors.
Collapse
Affiliation(s)
- F R Kandeel
- The Leslie and Susan Gonda (Goldschmied) Diabetes and Genetic Research Center, Department of Diabetes, Endocrinology & Metabolism, City of Hope National Medical Center, Duarte, California 91010, USA. fkandeel.coh.org
| | | | | |
Collapse
|
15
|
Isen K, Sinik Z, Alkibay T, Sezer C, Sözen S, Atilla S, Ataoglu O, Isik S. Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. Int J Urol 2001; 8:42-8. [PMID: 11240824 DOI: 10.1046/j.1442-2042.2001.00243.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE To determine whether magnetic resonance imaging (MRI) or quantitative color-imaged morphometric analysis (MA) of the prostate gland are related to the clinical response to terazosin. METHODS Thirty-six male patients with symptomatic benign prostatic hyperplasia (BPH) with a serum prostate-specific antigen level of 4-10 ng/mL underwent MRI with body coil, transrectal prostate ultrasonography and biopsy prior to terazosin therapy. For MRI-determined stromal and non-stromal BPH, the ratio of the signal intensity of the inner gland to the obturator internus muscle was evaluated. Histologic sections were stained with hematoxylin and eosin. The MA of the specimens was performed by Samba 2000. Results of the two techniques were interpreted according to the terazosin therapy results. RESULTS The mean stromal percentage was 60.5 +/- 18.0%. No statistically significant relationship was found between the clinical outcome of terazosin and the MRI findings. The MA results showed a significant relationship between the percentage of stroma and the percent change of the peak urinary flow rate, but not with the percent change of the international prostate symptom score after terazosin therapy (P < 0.05). CONCLUSION Magnetic resonance imaging alone is not sufficient in predicting the response to terazosin therapy. Morphometric analysis of BPH tissue composition can be used in predicting the clinical outcome of terazosin therapy but it is suitable only in patients for whom prostatic biopsy is necessary in order to rule out prostate cancer.
Collapse
Affiliation(s)
- K Isen
- Department of Urology, Karaelmas University School of Medicine, Zonguldak, Turkey
| | | | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
TRANSURETHRAL THERMOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA SIGNIFICANTLY DECREASES INFRAVESICAL OBSTRUCTION: RESULTS IN 134 PATIENTS AFTER 1 YEAR. J Urol 1999. [DOI: 10.1016/s0022-5347(05)68566-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
18
|
Elbadawi A. Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. I. Symptoms and urodynamics. Urology 1998; 51:62-72. [PMID: 9610560 DOI: 10.1016/s0090-4295(98)00070-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- A Elbadawi
- State University of New York, Health Science Center, Department of Pathology, Syracuse 13210, USA
| |
Collapse
|
19
|
Elbadawi A. Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. II. Pathology and pathophysiology. Urology 1998; 51:73-82. [PMID: 9610561 DOI: 10.1016/s0090-4295(98)00069-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- A Elbadawi
- State University of New York, Health Science Center, Department of Pathology, Syracuse 13210, USA
| |
Collapse
|
20
|
Hallin A, Berlin T. Transurethral microwave thermotherapy for benign prostatic hyperplasia: clinical outcome after 4 years. J Urol 1998; 159:459-64. [PMID: 9649263 DOI: 10.1016/s0022-5347(01)63948-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE We describe long-term results of transurethral microwave thermotherapy. We determined pretreatment variables favorable for the outcome. MATERIALS AND METHODS We followed for 4 years 187 patients treated with Prostatron software 2.0.* Preoperative evaluations consisted of score, cystoscopy, transrectal ultrasonography, urine flow and residual volume measurements. Followup examinations with score and urodynamics were performed for 4 years after transurethral microwave thermotherapy. Kaplan-Meier plots and logistic regression were used for statistical analyses. RESULTS A decrease in the number of satisfied patients was noted from 62% at 1 year after transurethral microwave thermotherapy to 23% at 4 years. Initial decrease in score and increase in urine flow were followed by increase in score and decrease in flow at the 4-year followup of the 56 patients who had not received supplementary benign prostatic hyperplasia (BPH) treatment. The Kaplan-Meier analysis estimated the median time for need of supplementary BPH treatment to be 45 months. Pretreatment urine flow greater than 10 ml. per second and an irritative score less than 5 were the only factors related to a favorable outcome. Prostate volume or energy delivered to the prostate did not influence the result. CONCLUSIONS Four years after transurethral microwave thermotherapy 23% of the initially treated group were satisfied with the result. Two-thirds had received supplementary BPH treatment. Preoperatively less obstructed patients and those with low initial irritative scores responded more favorably to transurethral microwave thermotherapy treatment.
Collapse
Affiliation(s)
- A Hallin
- Department of Urology, Huddinge University Hospital, Karolinska Institute, Sweden
| | | |
Collapse
|
21
|
Affiliation(s)
- P Mátyus
- Semmelweis University of Medicine, Institute of Organic Chemistry, Budapest, Hungary
| | | |
Collapse
|
22
|
Roehrborn CG, Oesterling JE, Olson PJ, Padley RJ. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial. Urology 1997; 50:556-61. [PMID: 9338731 DOI: 10.1016/s0090-4295(97)00302-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVES To prospectively analyze whether the treatment of men with clinically benign prostatic hyperplasia (BPH) with alpha blocking agents affects the serum prostate-specific antigen (PSA) levels, and to determine the magnitude of such effect. METHODS Serial PSA measurements were performed using the Abbott IMx assay over 1 year in 134 men over the age of 55 years participating in the Hytrin Community Assessment Trial (HYCAT). HYCAT is a 1-year, randomized, placebo-controlled, double-blinded study of the alpha1-adrenergic antagonist terazosin. All men had lower urinary tract symptoms and a clinical diagnosis of BPH with an American Urological Association (AUA) symptom index of 13 points or more, an AUA bother score of 8 points or more, and a peak urinary flow rate of less than 15 mL/s. PSA was measured at baseline and at 8, 26, 39, and 52 (end of study) weeks. RESULTS Baseline serum PSA levels weakly correlated with patients' age at study entry, and modestly with residual urine (positive correlation) and peak flow rate (negative correlation), although none of the levels were statistically significant. Changes of serum PSA during the course of the study did not correlate with either one of the symptom severity or bother assessment tools, residual urine, or peak flow rate. Mean PSA increased from a baseline of 2.5+/-0.22 ng/mL (mean+/-SE) by 0.5+/-0.11 ng/mL in the placebo-, and from 2.7+/-0.23 ng/mL by 0.3+/-0.11 ng/mL in the terazosin-treated patients (P = 0.36 by ANOVA). There were no differences in the changes in serum PSA when patients were stratified by decade of life according to the age-specific PSA reference ranges, or by the final dose of terazosin (2, 5, or 10 mg daily). CONCLUSIONS The treatment of men with lower urinary tract symptoms and clinical BPH with the alpha1-adrenergic antagonist terazosin does not affect serum PSA concentration, and thus does not confound longitudinal monitoring of serum PSA levels in patients at risk for prostate carcinoma.
Collapse
Affiliation(s)
- C G Roehrborn
- Department of Urology, University of Texas Southwestern Medical Center, Dallas 75235-9110, USA
| | | | | | | |
Collapse
|
23
|
Weijers RE, Zambon JV, Kessels AG, de Bruïne AP. On the prediction of the histologic composition of benign prostatic hyperplasia based on clinical and MRI parameters. Prostate 1997; 32:179-87. [PMID: 9254897 DOI: 10.1002/(sici)1097-0045(19970801)32:3<179::aid-pros4>3.0.co;2-g] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The histologic composition of prostate adenoma seems related to the development of clinical benign prostatic hyperplasia (BPH). Therefore, a new noninvasive prediction model as an alternative for biopsies was investigated. METHODS In 19 patients, the data of a routine preoperative workup for transurethral resection (TURP) and of an additional MRI-examination were related to the results of morphometry on TURP-tissue. RESULTS Statistical analysis identified age of the patient and MRI-volumetrics of the prostate adenoma as best predictors of the epithelial fraction, with a 95% confidence interval of at least 5% (range, 9-14%) (R2 = 50%). CONCLUSIONS This prediction model is sufficiently accurate to categorize a population of patients into histologic subgroups. It seems very likely that this method will be of use as an investigative tool in medical trials to provide insight into the pathogenesis of clinical BPH and into treatment strategies for the individual patient.
Collapse
Affiliation(s)
- R E Weijers
- Department of Radiology, Academic Hospital Maastricht, The Netherlands
| | | | | | | |
Collapse
|
24
|
D'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of followup. J Urol 1997; 158:120-5. [PMID: 9186336 DOI: 10.1097/00005392-199707000-00035] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
PURPOSE We compared the outcome of transurethral resection of the prostate and high energy microwave thermotherapy in patients with benign prostatic hyperplasia. MATERIALS AND METHODS Of 52 patients with symptomatic benign prostatic hyperplasia 21 (mean age plus or minus standard deviation 69.6 +/- 8.5 years) were treated with transurethral resection of the prostate and 31 (mean age 69.3 +/- 5.9 years) were treated with high energy microwave thermotherapy. Patients were assessed using the Madsen symptom score, measurements of voiding parameters, transrectal ultrasound and cystometry, including pressure-flow analyses. Examinations were repeated at fixed intervals for up to 12 months after treatment. RESULTS After transurethral resection and thermotherapy there was significant improvement in all clinical parameters. At 1 year of followup symptomatic improvement was 78% in the transurethral resection group versus 68% in the thermotherapy group, with improvements in free flow rate of 100 and 69%, respectively. Both groups had significant relief of bladder outlet symptoms. No serious complications occurred in either group, while 1 patient in each group required repeat treatment. CONCLUSIONS Satisfactory results were obtained after both treatments, with improvements following high energy microwave thermotherapy being in the same range as those after transurethral resection of the prostate.
Collapse
Affiliation(s)
- F C D'Ancona
- Department of Urology, University Hospital Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|
25
|
Comeri G. Clinical Experiment Comparing 3 Pharmacological Treatments of Benign Prostatic Hypertrophy: Terazosin Vs. Finasteride Vs. Terazosin + Finasteride. Urologia 1997. [DOI: 10.1177/039156039706400309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The tone of the smooth prostate muscle and the presence of hyperplastic tissue represent the dynamic and passive components respectively of the obstructive symptomatology present in benign prostatic hyperplasia (BPH). The contractile properties are mediated primarily by the alpha-1 type adrenergic receptors, which are found in great numbers in the stroma of the gland and in the prostatic capsule. The use of Terazosin, a selective alpha-1 blocker, has proved to be effective in the improvement of BPH symptoms associated with the hypertone of the smooth muscle. The assumption that androgens play an important role in hypertrophy of the prostate has introduced drugs into the treatment which are capable of blocking the synthesis and the action of testosterone and, in particular, dihydrotestosterone (DHT). Finasteride is an inhibitor of 5-alpha-reductase, the enzyme inside the prostatic epithelial cells which converts the testosterone into DHT. A multicentre study has therefore been carried out aimed at assessing, after 9 months treatment, the efficacy and tolerability of three pharmacological treatments: Terazosin, Finasteride and a combination of the two, in 146 patients with symptomatic BPH. Results of the study indicate that the drugs were well tolerated and that the efficacy in resolving the obstructive symptomatology was particularly accentuated and rapid in the groups treated with Terazosin, the action of which, in this respect, has proved to be more significant than that of Finasteride.
Collapse
Affiliation(s)
- G. Comeri
- Divisione Urologica - Ospedale S. Anna - Como
| |
Collapse
|
26
|
Takeda M, Hatano A, Komeyama T, Koizumi T, Mizusawa T, Kanai T, Tomita Y, Maruyama K, Nagatomo T. Alpha-1 adrenoceptor subtypes (high, low) in human benign prostatic hypertrophy tissue according to the affinities for prazosin. Prostate 1997; 31:216-22. [PMID: 9180931 DOI: 10.1002/(sici)1097-0045(19970601)31:4<216::aid-pros2>3.0.co;2-i] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND A novel classification of alpha-1 adrenoceptor subtypes (High, Low) was applied to human benign prostatic hypertrophy (BPH) tissue. METHODS Human BPH specimens were examined by a radioligand binding assay method using 3H-prazosin, and those data were compared with preoperative therapies. RESULTS (1) Scatchard analysis showed a high-affinity site (Kd:27.18 +/- 6.41 pM; Bmax:9.29 +/- 0.98 fM/mg protein; mean +/- SE) as alpha 1H, and a low-affinity site (Kd: 4088.0 +/- 744.34 pM, Bmax: 140.81 +/- 19.98 fM/mg protein) as alpha 1L subtype, for prazosin. (2) The Kd and Bmax were not different in the nontreated group (n = 5), alpha 1 blocker group (n = 5), and antiandrogen group (n = 5), in either alpha 1-high affinity or alpha 1-low affinity subtype. (3) Phenoxybenzamine had different pKi values for the above two adrenoceptor subtypes. Scatchard analysis showed that alpha 1-high affinity binding site disappeared in the presence of 1 microM of phenoxybenzamine, and the Kd and Bmax values in the presence of 1 microM of phenoxybenzamine were almost identical to the alpha 1-low affinity site of the two subtypes. CONCLUSIONS Human BPH tissue possesses both alpha 1H- and alpha 1L-adrenoceptor subtypes according to the affinities for prazosin, and only the alpha 1H subtype can be completely inhibited by some concentration of phenoxybenzamine. Treatment by alpha 1 blocker may not change the conditions of alpha 1-adrenoceptors in prostatic tissue.
Collapse
Affiliation(s)
- M Takeda
- Department of Urology, Niigata University, School of Medicine, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Lepor H, Nieder A, Feser J, O'Connell C, Dixon C. Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology 1997; 49:476-80. [PMID: 9123722 DOI: 10.1016/s0090-4295(96)00504-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVES To determine if men with normal peak urinary flow rates (PFR) and prostatism respond to terazosin. METHODS Forty-one men over the age of 50 years with an American Urological Association (AUA) symptom score greater than 8, postvoid residual urine volume (PVR) less than 300 mL, and no clinical or biochemical evidence of prostate cancer were treated with terazosin independent of the baseline PFR. The effect of terazosin on the AUA symptom score and PFR were compared for subjects with a PFR of 15 mL/s or less (group I) and those with a PFR greater than 15 mL/s (group II). RESULTS The baseline age, AUA symptom score, prostate volume, and PVR were not significantly different between the two groups. The mean changes in AUA symptom score were -45.0% and -49.5% for groups I and II, respectively. The mean changes in PFR were 7.0% and -26.6% for groups I and II, respectively. CONCLUSIONS The effect of terazosin on AUA symptom score is independent of baseline PFR, indicating that the mechanism of action of terazosin is not exclusively mediated by reduction of bladder outlet obstruction. Randomized controlled studies are required to confirm this provocative observation.
Collapse
Affiliation(s)
- H Lepor
- Department of Urology, New York University School of Medicine, New York, New York 10016, USA
| | | | | | | | | |
Collapse
|
29
|
Langenstroer P, Tang R, Divish B, Opgenorth T, Shapiro E, Lepor H. Endothelins in Canine Genitourinary Tissues. J Urol 1997. [DOI: 10.1097/00005392-199703000-00103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Sing R, Emerson L, Morales A. Prostatic microwave therapy: A pilot study for technology assessment. Urologia 1997. [DOI: 10.1177/039156039706400116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective. The Genemed Genetherm S 150 is an easy to use and comparatively inexpensive device for administering prostatic microwave therapy. This study was aimed at testing the efficacy and safety of this machine in a pilot study. Methods. Sixteen patients with benign prostatic hypertrophy participated in the study, but only fourteen were evaluable. All received one hour of microwave therapy where the mean temperature was 45.7±0.2 °C. Symptom scores (International Prostate Symptom Score and Quality of Life Assessment), peak flow rates and post void residuals were used to evaluate participants prior to and three months following their treatment. Results. The results of this study show a statistically significant improvement in mean symptom scores. There was no significant change in mean peak flow rates while a statistically significant increase in mean post void residual occurred. Individually, however, only one patient experienced an improvement in all of the above parameters. There were no undesirable side effects during or after treatment. Conclusions. We conclude that the results of this pilot study do not warrant further study of this device, despite its practicality and safety.
Collapse
Affiliation(s)
- R. Sing
- Department of Urology - Queen's University - Kingston - Ontario (Canada)
| | - L Emerson
- Department of Urology - Queen's University - Kingston - Ontario (Canada)
| | - A. Morales
- Department of Urology - Queen's University - Kingston - Ontario (Canada)
| |
Collapse
|
31
|
Polat O, Ozbey I, Gül O, Demirel A, Bayraktar Y. Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase. Int Urol Nephrol 1997; 29:323-30. [PMID: 9285305 DOI: 10.1007/bf02550930] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha-reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year. Prostatic volume, maximal urine flow rate, AUA symptom scoring, residual urine volume and prostate-specific antigen (PSA) levels were evaluated at 3, 6, 9 and 12 months. In the first 6 months prostatic volume decreased rapidly (20.5%), in the second 6 months it decreased slowly and reached the maximal rate (23.3%). Maximal urine flow rate increased in the second 6 months. AUA symptom scores decreased first at 3 months and were 4.6 points lower at the end of the 12th month. There were no significant changes in residual volume. The 5 alpha-reductase inhibitor caused a 50% decrease in PSA levels, like in other studies. Because of the prolonged use of the drug, treatment with 5 alpha-reductase inhibitor is not tolerated by many patients and being expensive its future in the pharmacotherapy of BPH is unclear.
Collapse
Affiliation(s)
- O Polat
- Department of Urology, Atatürk University School of Medicine, Research Hospital, Erzurum, Turkey
| | | | | | | | | |
Collapse
|
32
|
Ishigooka M, Hayami S, Hashimoto T, Suzuki Y, Ichiyanagi O, Nakada T. Effect of the alpha-1 adrenoceptor blocker on tissue norepinephrine contents in human benign prostatic hyperplasia. Int Urol Nephrol 1997; 29:195-200. [PMID: 9241547 DOI: 10.1007/bf02551341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
To see the effect of the alpha-adrenergic blocking agent on tissue norepinephrine contents of the prostate, norepinephrine (NE) levels were investigated in patients with symptomatic benign prostatic hyperplasia (BPH). Morphometrical analyses were also performed to detect the differences in tissue composition. Nineteen patients were subdivided into two groups. Patients in Group 1 were given tamsulosin hydrochloride (0.2 mg/day) for at least 4 weeks before transurethral resection of the prostate (TURP), while patients in the control group (Group 2) underwent no previous treatment for BPH before TURP. Tissue NE contents were investigated by high performance liquid chromatography on a chip of the prostate obtained by TURP. These two groups were closely similar in age distribution, prostatic size, results of preoperative symptom scoring and relative proportion of smooth muscle component within the evaluated specimen. In the present series, tissue NE contents in these groups were not statistically different (p = 0.64). Chronic and acute administration of the alpha-1 antagonist did not apparently influence the tissue NE level in patients with BPH.
Collapse
Affiliation(s)
- M Ishigooka
- Department of Urology, Yamagata University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|
33
|
Tazaki H, Baba S, Nakamura K, Tachibana M, Nakashima J, Nakagawa K, Guchi N. Newly Developed Equipment and Methods in the Treatment of BPH: Analysis of Present Status. Int J Urol 1996. [DOI: 10.1111/j.1442-2042.1996.tb00341.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, Padley RJ. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996; 47:159-68. [PMID: 8607227 DOI: 10.1016/s0090-4295(99)80409-9] [Citation(s) in RCA: 149] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
OBJECTIVES To determine the clinical effectiveness and safety of alpha(1)-blockade therapy versus placebo in the treatment of men with moderate to severe symptoms of prostatism in a community-based population under usual care conditions. METHODS The Hytrin Community Assessment Trial is a prospective, placebo-controlled, randomized, double-blinded, 1-year clinical trial, conducted at 15 academic medical centers (regional sites) and 141 private urology practices (satellite sites). A total of 2084 men at least 55 years old with moderate to severe symptoms of benign prostatic hyperplasia (BPH) as determined by an American Urological Association (AUA) Symptom Score (AUA-SS) of 13 or more points and a bother score (AUA-BS) of 8 or more were enrolled. Randomized patients at regional sites were required to have a peak urinary flow rate less that 15 mL/s with voided volume of at least 150 mL. Treatment with terazosin was initiated with 1 mg daily for 3 days, followed by 2 mg daily for 25 days. Thereafter, patients were titrated stepwise to 5 or 10 mg if they failed to achieve a 35% or greater improvement in the AUA-SS. Primary outcome measures were AUA-SS, AUA-BS, BPH Impact Index (BII), disease-specific quality of life (QQL) score, and treatment failure as defined as discontinuation due to persistent or worsening symptoms or need for surgical intervention for BPH. Secondary outcome measures were peak urinary flow rate and postvoid residual urine volume. RESULTS AUA-SS (0 to 35 point scale) improved from a baseline mean of 20.1 points by 37.8% during terazosin (n=976) and by 18.4% during placebo (n=973) treatment (P<0.001). Similarly, statistically superior improvements were observed in regard to the AUA-BS, BII, and the QQL score in the terazosin-treated patients. Peak urinary flow rate improved from a baseline of 9.6 mL/s (both regional treatment groups) by 2.2 mL/s in the terazosin group (n=137) and by 0.7 mL/s in the placebo group (n=140) (P< or = 0.05). Treatment failure occurred in 11.2% of terazosin- and 25.4% of placebo-treated patients (P<0.001; Kaplan-Meier adjusted withdrawal rates of 365 days). Withdrawal from study drug treatment due to adverse events occurred in 19.7% of terazosin- and 15.2% of placebo-treated patients (P<0.001). CONCLUSIONS Terazosin given once daily in a dose ranging from 2 to 10 mg in community-based urology practices under conditions simulating usual care is effective in reducing the symptoms, perception of bother, and the impairment of QQL due to urinary symptoms in men with moderate to severe symptoms of prostatism. This effect is superior to placebo and maintained over 12 months of follow-up. Clinical research outcome studies in BPH can be conducted in community-based practices, thus simulating as closely as possible "usual care" conditions.
Collapse
Affiliation(s)
- C G Roehrborn
- Division of Urology, University of Texas Southwestern Medical Center, Dallas 75235-9110, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Tazaki H, Baba S, Nakamura K, Tachibana M, Nakashima J, Nakagawa K, Deguchi N. Newly developed equipment and methods in the treatment of BPH: analysis of present status. Int J Urol 1996; 3:S48-52. [PMID: 24304024 DOI: 10.1111/j.1442-2042.1996.tb00086.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Benign prostatic hyperplasia (BPH) is the most common disease among the aged male population. A variety of symptoms are mainly caused by obstructive changes at the prostatic urethra. Transurethral resection (TURP) has been the gold standard of treatment, but new equipment and methods such as TUMT, HIFU, TUNA, and laser prostatectomy have been developed and are being tested for clinical application. Our experience with new equipment and methods show that their effectiveness has yet to be conclusively evaluated by objective parameters, while subjective improvements have been seen with less invasive treatments such as TUMT, HIFU and TUNA. Laser prostatectomy confirmed its advantages in hemostasis but comparison of each treatment is difficult because of different pathological changes created by different energy sources shown by MRI. Further studies are required to examine the new equipment and methods and for identification of the treatment of choice for BPH.
Collapse
Affiliation(s)
- H Tazaki
- Departments of Urology, School of Medicine, Keio University, Tokyo, Japan Kidney Disease Medical Center, Saitama Medical School, Saitama, Japan
| | | | | | | | | | | | | |
Collapse
|
36
|
Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Curr Ther Res Clin Exp 1995. [DOI: 10.1016/0011-393x(95)85063-5] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Cowles RS, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, Zabbo A. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 1995; 46:155-60. [PMID: 7542818 DOI: 10.1016/s0090-4295(99)80185-x] [Citation(s) in RCA: 124] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVES Transurethral resection of the prostate (TURP) represents the accepted standard of surgical therapy for the management of symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH). However, this is a major operative procedure associated with significant perioperative morbidity. Visual laser ablation of the prostate (VLAP) utilizing a neodymium:yttrium-aluminum-garnet laser represents a new technologic approach to the surgical management of BPH. We compared the relative safety and efficacy of these two surgical approaches in a prospective, randomized trial. METHODS At 6 investigational sites in the United States, 115 men with symptomatic BPH more than 50 years of age and not in retention, were randomly assigned to undergo either TURP (59 patients) of VLAP (56 patients). VLAP patients received a mean of 10,200 J of energy delivered in a mean of 5.5 intraprostate laser applications. At preoperative baseline, 3 months, 6 months, and 1 year postoperatively, all patients underwent clinical evaluations, including ultrasonic prostatic volume determination, standardized American Urological Association (AUA)-6 symptom score, peak urine flow, postvoid residual urine volume, and quality-of-life assessment. RESULTS Compared to TURP, the VLAP procedure required less time (23.4 versus 45.2 minutes; P < 0.01) and shorter hospitalization (1.8 versus 3.1 days, P < 0.01). VLAP was associated with a significantly lower rate of serious treatment-related complications compared to TURP (10.7% versus 35.6%; P < 0.01). Only One (2.2%) patient undergoing VLAP experienced a greater than 2.2 g/dL decrease in hemoglobin compared to 40% of TURP patients (P = 0.01). No patient in the VLAP group required blood transfusion compared with 3.4% of those undergoing TURP. Of the 115 patients, clinical outcomes measured at 1 year showed a mean improvement in AUA-6 symptom scores of -9.0 for VLAP compared with -13.3 for TURP (P < 0.04), mean increase in peak urinary flow rate of 5.3 cc/s for VLAP compared with 7.0 cc/s for TURP (P = 0.27), and mean decrease in postvoid residual urine volume of -55.4 cc for VLAP compared with -138.8 cc for TURP (P < 0.01). At 1 year, 78.2% of patients undergoing VLAP indicated that their quality of life was improved compared with 93.0% of patients undergoing TURP (P = 0.03). When compared with TURP, treatment of BPH with VLAP is associated with less hemoglobin decrease, a lower likelihood of serious complication, and requires less procedure time and a shorter hospital stay. Through a 1-year follow-up, VLAP produced significant improvement over baseline in objective and subjective outcome measures. However, for 1-year improvement in AUA-6 symptom score, postvoid residual urine volume, and quality of life, VLAP was less effective than TURP. CONCLUSIONS In this initial study in the United States, with relatively low-energy laser applications, VLAP did not result in as complete a removal of prostatic tissue as did TURP. Considering the lower morbidity, shorter procedure and hospitalization times, and the degree of effectiveness that was achieved even at the low-energy doses used in this study, VLAP appears to be a viable and safe alternative to standard TURP.
Collapse
Affiliation(s)
- R S Cowles
- Atlanta Center for Urology, Georgia; USA
| | | | | | | | | | | | | |
Collapse
|
38
|
Nakamura K, Baba S, Fukazawa R, Homma Y, Kawabe K, Aso Y, Tozaki H. Treatment of benign prostatic hyperplasia with high intensity focused ultrasound: an initial clinical trial in Japan with magnetic resonance imaging of the treated area. Int J Urol 1995; 2:176-80. [PMID: 8536134 DOI: 10.1111/j.1442-2042.1995.tb00449.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND High intensity focused ultrasound (HIFU) is a method of delivering acoustic energy to a focal point and is expected to induce tissue thermal ablation. Transrectal HIFU was applied to symptomatic benign prostatic hyperplasia (BPH) for relief of intravesical obstruction without injury to surrounding tissue. The clinical effectiveness and safety of transrectal HIFU were investigated. METHODS Thirty-seven Japanese men with symptomatic BPH were treated with HIFU. The treatment was minimally invasive; operating time was less than 40 minutes, and a posttreatment indwelling catheter was left in place for 3-4 days. RESULTS The maximum urinary flow rate (ml. per second) increased from 7.6 +/- 0.6 to 9.3 +/- 0.6 at three months in 37 patients (P < 0.05). During the same period the International Prostatic Symptom Score and Quality of Life score (points) decreased from 23.6 +/- 1.4 to 10.5 +/- 0.3, 5.2 +/- 0.3 to 2.6 +/- 0.1 (P < 0.001), respectively. Overall response estimated by these three individual parameters were as follows; excellent 18.9%, good 48.6%, fair 10.8% and poor 21.6% at three months. Magnetic resonance imaging using an endorectal coil showed coagulative necrosis defined in the therapy zone at one month after treatment. Side effects were transient urinary retention in six patients (16.2%), gross hematuria in four patients (10.8%) and hematospermia in four patients (10.8%). There was almost no intraoperative blood loss. CONCLUSIONS Transrectal HIFU treatment of symptomatic BPH is safe, reduces symptoms significantly, and leads to a slight increase in uroflow.
Collapse
Affiliation(s)
- K Nakamura
- Department of Urology, School of Medicine, Keio University, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
39
|
Prostatic Histology in Secondary Transurethral Resection of the Prostate. J Urol 1995. [DOI: 10.1097/00005392-199507000-00041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Affiliation(s)
- Morten Jonler
- Department of Surgery, Division of Urology, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin
| | - Reginald C. Bruskewitz
- Department of Surgery, Division of Urology, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin
| |
Collapse
|
41
|
|
42
|
Abstract
Continuing experience with Nd:YAG noncontact sidefiring laser fibers over the past 4 years has shown encouraging results. Thus far, of the 198 patients treated with the 60 W/60 seconds technique since October 1990, a total of 74 were available for long-term evaluation (69 at 12 months and 29 at 24 months). The AUA Symptom Scores, Qmax (peak uroflow rates), and postvoiding residual urine volumes demonstrated marked improvement. The complications included 16 instances of recurrent obstructive symptoms necessitating revision. Three patients suffered urinary tract infections, two patients developed bladder neck stenosis, four anticoagulated patients with clot retention required blood transfusions, and three patients had epididymoorchitis. Follow-up at 12 and 24 months showed sustained reduction in AUA Symptom Scores and maintained improvement of the peak flow rates and residual volumes. These results demonstrate the safety and clinical applicability of laser ablation of the prostate and its potential usefulness as a less invasive therapy for benign hyperplasia.
Collapse
Affiliation(s)
- A J Costello
- Department of Urology, St. Vincent's Hospital, Melbourne, Australia
| | | | | |
Collapse
|
43
|
Kaplan SA, Chiou RK, Morton WJ, Katz PG. Long-term experience utilizing a new balloon expandable prostatic endoprosthesis: the Titan stent. North American Titan Stent Study Group. Urology 1995; 45:234-40. [PMID: 7855972 DOI: 10.1016/0090-4295(95)80011-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVES To determine the long-term safety and efficacy of the Titan endoprosthesis as a therapeutic alternative in the management of men with bladder outlet obstruction. METHODS One hundred forty-four patients (mean age, 73.5 years +/- 4.2) had placement of the Titan stent. The stents were inserted under direct vision and expanded to 33 F using a balloon catheter. Of the 144 patients, 59 (41%) were in urinary retention and 85 (59%) presented with moderate to severe symptoms of prostatism. Patients were assessed at baseline and in follow-up at 1, 3, 6, 12, 18, and 24 months. Parameters of evaluation included the Madsen-Iversen symptom questionnaire, peak flow rate (Qmax), postvoid residual urine volume (PVR), and incidence of adverse events. RESULTS At 24 months, for the retention cohort, symptoms, Qmax, and PVR were 5.21 +/- 0.81, 11.34 +/- 1.12 mL/s, and 31.00 +/- 12.8 mL, respectively (P < 0.002). For patients with symptoms of bladder outlet obstruction, the results were as follows at 24 months: (1) symptoms decreased from 15.89 +/- 0.47 to 9.33 +/- 0.86 (P < 0.001); (2) Qmax increased from 8.59 +/- 0.41 mL/s to 11.43 +/- 1.12 mL/s (P < 0.001); and (3) PVR decreased from 116.94 +/- 19.95 mL to 74.4 +/- 36.2 mL (P < 0.03). There were minimal complications; stents were removed from 28 patients (19%) because of migration, 10 of which were placed by one investigator. CONCLUSIONS When properly placed, the Titan stent was an effective therapeutic alternative to prostatectomy or long-term catheterization in high-risk obstructed patients or those in urinary retention.
Collapse
Affiliation(s)
- S A Kaplan
- Department of Urology, College of Physicians & Surgeons, Columbia University, New York, New York
| | | | | | | |
Collapse
|
44
|
Schulman CC. Turapy--transurethral ablation prostatectomy by high temperature radiofrequency--preliminary results of a multicenter study. Nihon Hinyokika Gakkai Zasshi 1995; 86:76-81. [PMID: 7534841 DOI: 10.5980/jpnjurol.86.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Thermal treatment of BPH has been introduced several years ago as an alternative treatment modality for patients suffering from symptomatic BPH. The initial temperatures ranged from 44.5 to 48 degrees C. With these temperatures, about 60-70% of the patients showed significant improvement of their subjective, mainly irritative symptoms with only mild changes in their obstructive parameters. In order to improve the therapeutic effects, increase in energy delivered allowing higher temperatures in the order to 70-100 degrees C was investigated regarding the feasibility, tolerance, pathological lesions and clinical effectiveness. A new radiofrequency technique, TURAPY--TransURethral Ablation Prostatectomy, an outpatient ablative BPH treatment has been introduced recently. The treatment is applied transurethrally with a helicoidal antenna without any cooling system. Temperature delivery in the order of medium 75 degrees C was applied during a medium time of 45 minutes. An ongoing multicenter study included 38 patients. 15 patients were operated by retropubic prostatectomy after 6-30 days, for a histopathology study and 23 eligible patients were entered in a clinical study and analyzed to determine the efficacy of the TURAPY treatment. The tolerance was excellent and although patients experienced initial heating sensation at the onset of treatment, as the temperature rose to 40-50 degrees C (as with previous modalities of thermotherapy), they did not experience further pain and the procedure was never stopped. Urinary retention was observed in about 80% of the patients, due to the extensive tissular destruction. These patients had suprapubic catheter inserted one day to a maximum of one week (medium 3 days).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
45
|
Noel H. Hypertension: complications and problems. JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS 1994; 6:540-8; quiz 549-51. [PMID: 7848742 DOI: 10.1111/j.1745-7599.1994.tb00908.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
46
|
Norman RW, Nickel JC, Fish D, Pickett SN. 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. BRITISH JOURNAL OF UROLOGY 1994; 74:542-50. [PMID: 7530115 DOI: 10.1111/j.1464-410x.1994.tb09181.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVES To determine the prevalence of symptoms associated with benign prostatic hyperplasia (BPH) in Canadian men, and to establish whether the traditional separation of these symptoms into obstructive and irritative categories is valid. SUBJECTS AND METHODS A probability sample of 508 Canadian men 50 years of age or older was surveyed by telephone. The survey questions and scoring system used were devised to allow estimation of symptom prevalence and were based on the frequency and severity of the symptoms. Using the data from respondents who had moderate to severe symptoms, a cluster analysis was utilized to analyse relationships among symptoms. RESULTS The most prevalent symptoms were nocturia (63%), weak stream (61%) and urinary frequency (46%). Urgency was reported by 18%, a sense of incomplete bladder emptying by 23%, intermittency by 18% and hesitancy by 13%. Using predefined cutoff scores, 23% of the respondents experienced moderate to severe symptoms associated with BPH; the prevalence of moderate to severe symptoms increased with age. The clusters were grouped on the basis of the symptoms driving them, with one cluster designated as 'moderates', two clusters designated as 'irritatives' and two designated as 'obstructives'. The moderates cluster was driven by respondents who had lower symptom scores evenly distributed across all symptoms. The irritatives and obstructives clusters were driven by respondents with higher scores for symptoms considered by convention to be irritative or obstructive in nature and, thus, were designated accordingly. Not all symptoms were discriminatory for irritative and obstructive symptom domains. CONCLUSIONS A large percentage of Canadian men 50 years of age or older experience symptoms commonly associated with BPH. The theoretical concept of irritative and obstructive symptom domains was supported partially by the cluster analysis. A clear typology of men with BPH symptoms could prove useful if treatments were found to be more effective for certain types of BPH symptoms. Thus these observations warrant further investigation into the differential effects of management approaches for BPH symptoms according to symptom clusters.
Collapse
Affiliation(s)
- R W Norman
- Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | | | |
Collapse
|
47
|
Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. BRITISH JOURNAL OF UROLOGY 1994; 74:579-84. [PMID: 7530121 DOI: 10.1111/j.1464-410x.1994.tb09187.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVE To address the long-term results of alfuzosin, an alpha 1-antagonist, in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS A 6-month, placebo-controlled study involving 518 patients was followed by two successive one-year, open extensions. Only centres who wished to continue the trial participated in the extensions; 131 patients entered the first extension, with 50 continuing into the second year extension. The results of the second year follow-up are presented here. RESULTS Depending on their initial randomization to either the placebo or alfuzosin arm, patients were treated with alfuzosin for 24 (n = 50) or 30 months (n = 22). The data collected on those 50 patients in comparison to baseline confirmed that the clinical efficacy observed in short/medium-term studies was maintained. A clinically significant improvement in urinary symptoms was observed; the Boyarsky score decreased from 8.7 (+/- 0.3) at baseline to 5.2 (+/- 0.3) at 24 months, with no deterioration in the objective parameters. In patients treated for 30 months (n = 22), symptomatic assessment and urodynamic parameters remained stable, indicating the sustained effectiveness of therapy. No serious or unexpected side-effect related to long-term exposure to alfuzosin was observed. No complications associated with BPH occurred. Two patients (4%) reported dizziness, neither of whom withdrew from the study. In this population, where 40% of patients were receiving concomitant cardiovascular therapy, no clinically significant change in standing systolic blood pressure, diastolic blood pressure or heart rate was apparent between baseline data and those at 24 months. CONCLUSION These data demonstrate the usefulness of long-term treatment with alfuzosin in patients with uncomplicated, moderate BPH.
Collapse
|
48
|
Kaplan SA, Soldo KA, Olsson CA. Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study. Urology 1994; 44:348-52. [PMID: 7521090 DOI: 10.1016/s0090-4295(94)80092-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVES In this pilot study, the effect of dosing schedule on the efficacy and safety of the long-acting alpha 1-adrenergic blocker doxazosin (DOX) was evaluated in 48 consecutive, normotensive men (mean age, 61.2 years) with symptoms of prostatism. METHODS In this titration to fixed dose study, patients were randomized into 1 of 4 treatment groups: (1) 4 mg DOX once in the AM (n = 12); (2) 4 mg DOX once in the PM (n = 12); (3) 8 mg DOX once in the AM (n = 12); and (4) 8 mg DOX once in the PM (n = 12). Parameters evaluated included Boyarsky symptom score (Sx), peak uroflow (Qmax), blood pressure, and occurrence of side effects. Once stabilized, patients were seen at 3-month intervals; follow-up ranged from 3 to 19 months (mean, 7.7). RESULTS Clinical improvement as determined by Sx and Qmax was similar for AM and PM groups with either 4 or 8 mg of DOX. Mean decreases in Sx at 3 months were 4.6, 4.2, 5.1, and 5.2 and at 6 months were 4.7, 4.7, 5.3, and 5.4 for the 4 mg AM, 4 mg PM, 8 mg AM, and 8 mg PM, respectively. Mean peak uroflow at 3 months increased 2.7, 2.9, 3.2, and 3.3 mL/s and at 6 months increased 2.6, 3.0, 3.4, and 3.5 mL/s for the 4 mg AM, 4 mg PM, 8 mg AM, and 8 mg PM, respectively (p < 0.05). Six patients (13%) were dropped from the study because of side effects (2 for fatigue, 2 for headache, 2 for dizziness): 5 during the titration phase (4 mg AM: 2; 8 mg AM: 2; 8 mg PM: 1), and 1 during the treatment phase (8 mg AM). CONCLUSIONS These data suggest that evening dosing does not diminish efficacy yet may enhance toleration of DOX. These preliminary results suggest that a larger prospective study is warranted to determine the optimal dosing and timing of DOX in the management of symptomatic benign prostatic hyperplasia.
Collapse
Affiliation(s)
- S A Kaplan
- Department of Urology, College of Physicians & Surgeons, Columbia University, New York, New York
| | | | | |
Collapse
|
49
|
Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44:46-51. [PMID: 7518981 DOI: 10.1016/s0090-4295(94)80008-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVES This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH). METHODS Six placebo-controlled trials (including two unpublished series) involving 996 patients provide the database for this evaluation. Six hundred thirty-six patients received terazosin from 1 to 20 mg daily for a total of 229 patient-years of exposure to terazosin. The most common final dose of terazosin was 10 mg once daily. RESULTS Side effects were generally mild or moderate in severity and resolved following cessation of therapy. Side effects resulted in premature withdrawal in 9% of terazosin-treated patients and 7% of placebo-treated patients (difference not significant). Dizziness (2.0%) and headache (1.1%) were the most common symptoms leading to premature withdrawal from the studies. Although postural symptoms and dizziness were slightly more common in those terazosin-treated patients 65 or more years old compared with patients less than 65 years old, this difference was not statistically significant. Only 4 of the 636 patients (0.6%) had syncopal episodes; 2 of these occurred at initiation of terazosin therapy or at dose escalation. Minimal reductions in blood pressure were observed in normotensive patients and patients with hypertension controlled by concomitant medication, whereas patients with untreated hypertension had substantial decreases in both systolic and diastolic blood pressures. Statistically significant increases in high density lipoprotein to cholesterol ratio and reductions in total cholesterol, low density lipoprotein, and triglycerides were also seen. CONCLUSIONS This combined analysis suggests that terazosin can be safely administered to both normotensive and hypertensive patients with symptomatic BPH.
Collapse
Affiliation(s)
- F C Lowe
- Department of Urology, St. Luke's, Roosevelt Hospital Center, New York, New York
| |
Collapse
|
50
|
de la Rosette JJ, de Wildt MJ, Alivizatos G, Froeling FM, Debruyne FM. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994; 44:58-63. [PMID: 7518982 DOI: 10.1016/s0090-4295(94)80010-3] [Citation(s) in RCA: 77] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVES A prospective, randomized placebo-controlled study was designed to exclude a placebo response in transurethral microwave thermotherapy (TUMT). METHODS During a sham procedure, the microwave applicator was installed in the urethra as in the real TUMT treatment and a complete procedure was simulated by the microwave delivery system (Prostatron). Any patient who entered this study had the option to request a second real TUMT treatment if, 3 months after the initial procedure, his condition had not improved. RESULTS A total of 48 patients were available for evaluation at 3 months and 28 at 6 months. The TUMT group had an average decrease of 7.3 points (from 13.2 to 5.9) in the Madsen symptom score, an average increase in flowrate of 3.4 mL/s (9.6 to 13.0), and an increase in voiding percentage of 9.6% (81.7 to 91.3). All improvements were statistically significant. In the sham group, the average Madsen score decreased from 12.1 to 8.2 points, the average flowrate decreased from 9.7 to 9.5 mL/s, and the voiding percentage increased from 80.8% to 84.3%. Only the change in symptom score was significant. In both groups, observations at the 3-month follow-up were similar to those after 6 and 12 months. Patients who had TUMT after sham treatment showed similar significant changes in symptom score and peak flow as observed in the original TUMT group. Patients who did not respond favorably to a first TUMT did not experience improvement after a second TUMT. CONCLUSIONS A placebo effect, although minimal, exists. This placebo response, however, accounts for little of the observed benefit of TUMT.
Collapse
Affiliation(s)
- J J de la Rosette
- Department of Urology, University Hospital, Nijmegen, The Netherlands
| | | | | | | | | |
Collapse
|